Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya

Table 6

Duration on ART and drug-resistant mutations among HIV-1 subtypes.

ART treatment duration	ART	HIV-1 subtypes	DRMs
<1 year	AZT/3TC/NVP	C	A62AV
	AZT/3TC/NVP	A1	L100LF, K103N
1–5 years	AZT/3TC/EFV	C	E138A
	AZT/3TC/NVP	C	E138A
	AZT/NVP/3TC/CPT	A1	M41ML, D67N, K70R, M184V, K219Q, G190A
	AZT/3TC/NVP	A1	G190A
	AZT/3TC/NVP	A1	M184V, L210W, A98G, Y181C
	TDF/3TC/EFV	A1	K70KR, T215TIN, K219KE
	TDF/3TC/EFV	D	L234LI
	TDF/3TC/EFV	C	E138A
	AZT, NVP, 3TC, CPT	A1	M41ML, D67N, K70R, M184V, K219Q, G190A
	NVP, AZT, 3TC, SPT	A1	M184V, A98G, K101E, V106VI, V179T, Y181C, G190S
>5 years	NVP, LUM, AZT, SPT	A1	M184IV, K103N, Y181C
	NVP, AZT, 3TC, SPT	D	K219N, L100LF, Y181F
	NVP, LUM, AZT, SPT	A1	L74LV, Y181YC, G190GA